Merck & Co. has agreed to acquire Cidara Therapeutics for approximately $9.2 billion, the companies said, in a deal designed to bolster the buyer’s antiviral portfolio with a Phase III drug designed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback